The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 06, 2016

Filed:

Feb. 17, 2012
Applicants:

Andrew Asher Protter, Palo Alto, CA (US);

Sarvajit Chakravarty, Mountain View, CA (US);

Inventors:

Andrew Asher Protter, Palo Alto, CA (US);

Sarvajit Chakravarty, Mountain View, CA (US);

Assignee:

Medivation Technologies, Inc., San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/55 (2006.01); A61K 31/54 (2006.01); C07D 513/16 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/46 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5383 (2006.01); A61K 31/542 (2006.01); A61K 31/553 (2006.01); C07D 451/00 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); C07D 471/16 (2006.01); C07D 471/22 (2006.01); C07D 487/04 (2006.01); C07D 487/16 (2006.01); C07D 498/16 (2006.01); C07D 498/22 (2006.01); C07D 471/08 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
C07D 513/16 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/46 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/542 (2013.01); A61K 31/55 (2013.01); A61K 31/553 (2013.01); C07D 451/00 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 471/14 (2013.01); C07D 471/16 (2013.01); C07D 471/22 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/16 (2013.01); C07D 498/16 (2013.01); C07D 498/22 (2013.01);
Abstract

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α. The compounds may also bind to and are an antagonist of the adrenergic receptor α; or the compounds are not antagonists of the adrenergic receptor αand the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.


Find Patent Forward Citations

Loading…